Multiracial participants in Alzheimer's research: scoping review and recommendations

IF 7.4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2026-07-01 DOI:10.1002/trc2.70276

Stacey Moeller, Katie Singsank, Grace Goodwin, Denise Lafont-Tanner, Elizabeth Lawrence, Brenna Renn, Samantha John

{"title":"Multiracial participants in Alzheimer's research: scoping review and recommendations","authors":"Stacey Moeller, Katie Singsank, Grace Goodwin, Denise Lafont-Tanner, Elizabeth Lawrence, Brenna Renn, Samantha John","doi":"10.1002/trc2.70276","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Evidence suggests that Alzheimer's disease (AD) presents differently across ethnoracial groups, producing disparate risk and resilience profiles that may be measured through neuropsychological data. Extant AD research primarily examines monoracial groups, despite the fact that Multiracial individuals make up more than 10% of the US population. Failure to incorporate data from Multiracial participants (those endorsing two or more racial identities) limits research and clinical efforts to address AD in minoritized communities. A scoping review examined the use of neuropsychological data from Multiracial participants within AD research. Three databases were searched (APA PsycInfo, Embase, and Web of Science) for studies containing ethnoracially minoritized groups. Two independent researchers reviewed articles and included studies that met the following criteria: published in 2000 (the year the US Census formally allowed self-identification of multiple races) or later, in English, US-based cohort (as race is a social construct), reported neuropsychological data, and the research was AD-related. Searches yielded 855 original articles. Following abstract review, 484 articles were screened in full, resulting in 19 articles that met the inclusion criteria. Most excluded articles (66.67%) contained vague racial descriptions (e.g., use of an undefined Other Race group), making it difficult to know whether Multiracial participants existed in the dataset. Roughly one-third (29.03%) of articles were excluded because they described only monoracial groups. Analysis of neuropsychological outcomes showed that most articles included Multiracial participant data in larger group-level analyses (e.g., normal cognition versus dementia) or grouped their data with other, less represented ethnic or racial groups (e.g., Other Races). This review demonstrates the paucity of research and need for intentional consideration of the inclusion of Multiracial participants in AD research. Recommendations to improve reporting of data from Multiracial participants are offered, including considerations for the anticipation and adaptation to changes in the social definitions of ethnicity and race.</p>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"12 3","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13322995/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Evidence suggests that Alzheimer's disease (AD) presents differently across ethnoracial groups, producing disparate risk and resilience profiles that may be measured through neuropsychological data. Extant AD research primarily examines monoracial groups, despite the fact that Multiracial individuals make up more than 10% of the US population. Failure to incorporate data from Multiracial participants (those endorsing two or more racial identities) limits research and clinical efforts to address AD in minoritized communities. A scoping review examined the use of neuropsychological data from Multiracial participants within AD research. Three databases were searched (APA PsycInfo, Embase, and Web of Science) for studies containing ethnoracially minoritized groups. Two independent researchers reviewed articles and included studies that met the following criteria: published in 2000 (the year the US Census formally allowed self-identification of multiple races) or later, in English, US-based cohort (as race is a social construct), reported neuropsychological data, and the research was AD-related. Searches yielded 855 original articles. Following abstract review, 484 articles were screened in full, resulting in 19 articles that met the inclusion criteria. Most excluded articles (66.67%) contained vague racial descriptions (e.g., use of an undefined Other Race group), making it difficult to know whether Multiracial participants existed in the dataset. Roughly one-third (29.03%) of articles were excluded because they described only monoracial groups. Analysis of neuropsychological outcomes showed that most articles included Multiracial participant data in larger group-level analyses (e.g., normal cognition versus dementia) or grouped their data with other, less represented ethnic or racial groups (e.g., Other Races). This review demonstrates the paucity of research and need for intentional consideration of the inclusion of Multiracial participants in AD research. Recommendations to improve reporting of data from Multiracial participants are offered, including considerations for the anticipation and adaptation to changes in the social definitions of ethnicity and race.

Abstract Image

查看原文本刊更多论文

阿尔茨海默病研究中的多种族参与者：范围审查和建议。

有证据表明，阿尔茨海默病（AD）在不同种族群体中的表现不同，产生了不同的风险和恢复能力，可以通过神经心理学数据来衡量。尽管多种族个体占美国人口的10%以上，但现有的AD研究主要是研究单一种族群体。未能纳入多种族参与者（支持两种或两种以上种族身份的参与者）的数据限制了在少数族裔社区解决阿尔茨海默病的研究和临床努力。一项范围审查检查了在AD研究中使用多种族参与者的神经心理学数据。检索了三个数据库（APA PsycInfo， Embase和Web of Science），以查找包含少数民族群体的研究。两名独立研究人员审查了文章，并纳入了符合以下标准的研究：发表于2000年（美国人口普查正式允许多种族自我认同的那一年）或之后，用英语，美国队列（因为种族是一种社会结构），报告了神经心理学数据，研究与ad相关。搜索产生了855篇原创文章。摘要综述后，对484篇文章进行了全文筛选，最终有19篇文章符合纳入标准。大多数被排除的文章（66.67%）包含模糊的种族描述（例如，使用未定义的Other Race组），使得很难知道数据集中是否存在多种族参与者。大约三分之一（29.03%）的文章被排除，因为它们只描述了单一种族群体。对神经心理学结果的分析表明，大多数文章在更大的群体水平分析中包含了多种族参与者的数据（例如，正常认知与痴呆），或者将他们的数据与其他较少代表的民族或种族群体（例如，其他种族）分组。这篇综述表明研究的缺乏和需要有意识地考虑在AD研究中纳入多种族参与者。提出了改进多种族参与者数据报告的建议，包括考虑到预期和适应族裔和种族的社会定义的变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.